Betamethasone Valerate, Usp + Clotrimazole, Usp + Gentamicin Sulfate, Usp

Verify with FDA CVM →

403 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
403
Total Reports
5
Deaths Reported
120.0%
Death Rate

Active Ingredients

Betamethasone Valerate, UspClotrimazole, UspGentamicin Sulfate, Usp

Administration Routes

Auricular (Otic)UnknownTopicalIntradermalTransdermal

Species Affected

Dog 393
Cat 7
Unknown 3

Most Affected Breeds

Unknown 80
Retriever - Labrador 34
Terrier - Yorkshire 17
Chihuahua 14
Boxer (German Boxer) 12
Pug 12
Pit Bull 12
Terrier - West Highland White 11
Retriever - Golden 10
Shepherd Dog - German 9

Most Reported Reactions

Deafness 313
PR-EAR(S), LESION(S) 47
Partial deafness 17
Loss of hearing 16
Hearing affected 13
Hearing decreased 7
Temporary deafness 7
Impaired hearing 5
Vomiting 4
Anorexia 3
Skin irritation 3
Diarrhoea 2

Outcome Breakdown

Ongoing
202 (52.2%)
Outcome Unknown
125 (32.3%)
Recovered/Normal
48 (12.4%)
Recovered with Sequela
7 (1.8%)
Euthanized
3 (0.8%)
Died
2 (0.5%)

Data Summary

Metric Value
Total adverse event reports 403
Reports involving death 5
Case-fatality rate (reported events) 120.0%
Distinct species in reports 3
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 3

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Betamethasone Valerate, Usp + Clotrimazole, Usp + Gentamicin Sulfate, Usp Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 403 adverse event reports referencing Betamethasone Valerate, Usp + Clotrimazole, Usp + Gentamicin Sulfate, Usp, including 5 reports in which the animal died — a 120.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Betamethasone Valerate, Usp, Clotrimazole, Usp, Gentamicin Sulfate, Usp. Reported administration routes include Auricular (Otic), Unknown, Topical, Intradermal. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Betamethasone Valerate, Usp + Clotrimazole, Usp + Gentamicin Sulfate, Usp reports are Dog (393 reports), Cat (7 reports), Unknown (3 reports), with Dog accounting for the largest share. Within those species, Unknown (80), Retriever - Labrador (34), Terrier - Yorkshire (17) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Betamethasone Valerate, Usp + Clotrimazole, Usp + Gentamicin Sulfate, Usp are Deafness (313), PR-EAR(S), LESION(S) (47), Partial deafness (17), Loss of hearing (16). Of the 387 reports with a coded outcome, Ongoing is the leading category at 52.2%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Betamethasone Valerate, Usp + Clotrimazole, Usp + Gentamicin Sulfate, Usp.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial